Consun Pharmaceutical Group (HKSE:01681) EV-to-EBIT : 2.14 (As of Jun. 10, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Consun Pharmaceutical Group's Enterprise Value is HK$2,070 Mil. Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$968 Mil. Therefore, Consun Pharmaceutical Group's EV-to-EBIT for today is 2.14.

The historical rank and industry rank for Consun Pharmaceutical Group's EV-to-EBIT or its related term are showing as below:

HKSE:01681' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.67 Med: 8.58 Max: 21.29
Current: 2.14

During the past 12 years, the highest EV-to-EBIT of Consun Pharmaceutical Group was 21.29. The lowest was 0.67. And the median was 8.58.

HKSE:01681's EV-to-EBIT is ranked better than
95.36% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.54 vs HKSE:01681: 2.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Consun Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2023 was HK$828 Mil. Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$968 Mil. Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 116.84%.

Consun Pharmaceutical Group EV-to-EBIT Historical Data

The historical data trend for Consun Pharmaceutical Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group EV-to-EBIT Chart

Consun Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

19.00

1.72

2.03

0.85

0.86

Consun Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															2.03	-	0.85	-	0.86

Competitive Comparison of Consun Pharmaceutical Group's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Consun Pharmaceutical Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's EV-to-EBIT falls into.

Consun Pharmaceutical Group EV-to-EBIT Calculation

Consun Pharmaceutical Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2070.456	/	967.959
	=	2.14

Consun Pharmaceutical Group's current Enterprise Value is HK$2,070 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$968 Mil.

Consun Pharmaceutical Group (HKSE:01681) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Consun Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	967.959	/	828.43509
	=	116.84 %

Consun Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2023 was HK$828 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$968 Mil.

Consun Pharmaceutical Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » EV-to-EBIT

Traded in Other Exchanges

C1P:Germany

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Executives

An Yubao	2101 Beneficial owner
Li Qian	2101 Beneficial owner
Central Success Developments Limited	2101 Beneficial owner
Aali Resources Limited	2201 Interest of corporation controlled by you
Bos Trustee Limited	2301 Trustee
Zhang Lihua	2202 Interest of your spouse
An Meng	2101 Beneficial owner
Double Grace International Limited	2101 Beneficial owner
Bos Trustee Limited As Trustee	2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines